Skip to content

A Pharmaco-Clinical Study Of Posta Dana W.S.R To Dandruff

A Pharmaco-Clinical study of Ahiphen seed(Papaver somniferum Linn)w.s.r.to Darunaka

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/08/035640
Enrollment
30
Registered
2021-08-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Ahiphen seed(khaskhas)churna locally: Ahiphen seed(khaskhas)churna with milk twice in week Control Intervention1: Not applicable: Not applicable

Sponsors

Govt Dhanwantri Ayurvedic college and hospital ujjain
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients having classical sign and symtom of darunaka

Exclusion criteria

Exclusion criteria: 1 patients below 15 years and above 50 years 2 patients suffering from dandruff other then scalp area 3 patients suffering from any acute or chronic metabolic nerurological immune compressed disorder 4. Thyroid disorders Diabetes mellitus

Design outcomes

Primary

MeasureTime frame
Changing in classical sign and symptoms of darunaka (At the time of baseline and at the end of the treatmentTimepoint: Changing in classical sign and symptoms of darunaka (At the time of baseline and at the end of the treatment

Secondary

MeasureTime frame
Assessment of chnange in the clinical parameters (on 15th day)Timepoint: Changing in classical sign and symptoms of darunaka (At the time of baseline and at the end of the treatment

Countries

India

Contacts

Public ContactDr shiromani Mishra

Govt dhanwantri Ayurvedic medical college and hospital

shiromishra@gmail.com9893158853

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026